Search
forLearn
5 / 801 resultslearn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
learn nonspecific group of glycoproteins
learn microbiota modulator
learn multipeptides
Research
5 / 342 results
research Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restriction of Treg TCRβ-chain, which highlights the immunopathological aspect of the disease
Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.
research Alopecia Areata
Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
research Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis
The document concludes that diagnosing and treating Human African Trypanosomiasis is challenging, but new treatments like fexinidazole are promising.
research Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects
Lupus treatment requires a combination of drugs and therapies, with research needed for new options.
research Symmetrical acrokeratoderma: A peculiar entity in China? Clinicopathologic and immunopathologic study of 34 new cases
Symmetrical Acrokeratoderma (SAK) may be a unique skin condition in China, lacking specific treatment and needing long-term monitoring.
Community Join
5 / 1000+ resultscommunity Proposed new pathogenesis model for androgenetic alopecia (AGA)
The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community DUPA, Non Responders and Connective Tissue Disorders
A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.